Skip to content
Screener

Celldex Therapeutics CLDX Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$15.0KMiss by $780.4K
EPS-$1.18Miss by $0.03
Revenue estimate$795.4K
EPS estimate-$1.15

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$722.6K
EPS estimate-$1.02

Financials

Q1 2026

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.11B+75.2%
Enterprise value$2.08B+74.4%
P/S2,438.2×+2,279×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0×0.0×
Current ratio8.9×-12.7×

Segments

By product

See full
Grant$15.0K-97.7%

FAQ

When did Celldex Therapeutics report Q1 2026 earnings?
Celldex Therapeutics (CLDX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Celldex Therapeutics's Q1 2026 revenue and EPS?
Celldex Therapeutics reported revenue of $15.0K and eps of $-1.18 for Q1 2026.
Did Celldex Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $795.4K by $780.4K. EPS missed the consensus estimate of $-1.15 by $0.03.
How did Celldex Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 97.8% from $695.0K a year earlier and eps declined 45.7% from $-0.81.
Where can I find Celldex Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-003153) and the 10-Q periodic report (0001104659-26-057113) directly on SEC EDGAR. The filing index links above go to sec.gov.